U.S. House · 117th Congress · H.R. 153
Protecting Consumer Access to Generic Drugs Act of 2021
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Bobby L. RushD-IL-1
- Introduced
- January 4, 2021, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (18)
17 Democrats, 1 Republican. Each member is shown with the party they were counted with on the day they signed on. How we count these
Original cosponsors
- Sean CastenD-IL-6
- Steve CohenD-TN-9
- Gerald E. ConnollyD-VA-11
- Mark DeSaulnierD-CA-11
- Joe NeguseD-CO-2
- Raul RuizD-CA-36
- Lauren UnderwoodD-IL-14
- Jefferson Van DrewR-NJ-2
Signed on later
- David ScottD-GA-13January 5, 2021
- Janice D. SchakowskyD-IL-9January 15, 2021
- David J. TroneD-MD-6January 15, 2021
- Peter WelchD-VT-ALJanuary 15, 2021
- Lisa Blunt RochesterD-DE-ALJanuary 25, 2021
- Ro KhannaD-CA-17January 25, 2021
- John B. LarsonD-CT-1January 25, 2021
- Ed CaseD-HI-1July 22, 2021
- Adam SmithD-WA-9July 22, 2021
- Susan WildD-PA-7March 1, 2022